Pacific Institute of Medical Research Announces Rebrand to CalNeuro Research Group
Pacific Institute of Medical Research has changed its name to CalNeuro Research Group. Located in Los Angeles, California, CalNeuro is committed to conducting cutting edge, compassionate clinical research. As an independent clinical research group specializing in disorders of the central nervous system, CalNeuro has compiled a remarkable team of distinguished physician specialists, each having contributed greatly to further advances in new therapies. The new name reflects a change in leadership and a renewed dedication to providing the Southern California community with access to new treatment options and exceptional clinical care.
CalNeuro is led by Alexander Bystritsky, M.D., Ph.D and Tanya Vapnik Ph.D. Dr. Bystritsky is a board-certified psychiatrist with a specialty in anxiety disorders. He currently serves as Director of both the UCLA Anxiety Disorder Program Psychiatry Department and UCLA Neuropsychiatric Institute & Hospital’s Partial Hospitalization Program for Treatment Resistant Anxiety Disorder and OCD. About his new role, Dr. Bystritsky says, “I am very excited about leading CalNeuro Research in their future endeavors and the opportunity to evaluate new medications for mental health.” Dr. Vapnik holds a doctorate in clinical psychology and currently works as a clinician, researcher, and educator at UCLA and runs her own successful private practice.
With over 60 years combined experience in clinical research, Dr. Bystritsky and Dr. Vapnik lead a dedicated team of professionals. CalNeuro’s practiced staff has worked with a diverse blend of patient volunteers with a range of neurologic and psychiatric conditions including depression, anxiety, OCD, Alzheimer’s, insomnia, migraine, fibromyalgia, addiction, and pain. CalNeuro conducts Phase 2 through Phase 4 clinical trials.
By conducting the highest quality clinical research in partnership with pioneering pharmaceutical companies, CalNeuro will remain committed to the mission of collecting clinical data of the highest quality about investigational medications and devices as novel therapeutics for a variety of psychiatric and neurologic conditions, with the highest level of ethics and patient safety.
For more information on this release, please contact Irina Lerner-Roiz at 310-208-7144.
Irina Lerner-Roiz, Clinical Trial Director